
Syndeio Biosciences
Developing rapid-acting therapies to enhance synaptic health and treat CNS disorders through novel synapse pharmacology.
Employees
Enterprise value
$360—540m
Authorizing premium user...
Developing rapid-acting therapies to enhance synaptic health and treat CNS disorders through novel synapse pharmacology.